Upregulation of DAB2IP Inhibits Ras Activity and Tumorigenesis in Human Pancreatic Cancer Cells
Open Access
- 24 April 2020
- journal article
- research article
- Published by SAGE Publications in Technology in Cancer Research & Treatment
Abstract
KRAS mutation-induced Ras activation plays an important role in the pathogenesis of pancreatic cancer, but the role of wild-type Ras and Ras GTPase-activating proteins remains unclear. The present study was designed to determine the expression spectra of Ras GTPase-activating proteins genes in pancreatic cancer cells, and the role of DAB2IP, a Ras GTPase-activating proteins gene, in the development and progression of pancreatic cancer. Following the analyses of the expression profiles of 16 Ras GTPase-activating proteins in 6 pancreatic cancer cell lines including Bxpc-3 (with wild-type KRAS), Capan-2, Sw1990, Aspc-1, CFPAC-1, and Panc-1 (with mutant KRAS) and 1 normal human pancreatic ductal epithelial cell line, H6C7, the expression of DAB2IP messenger RNA was further analyzed by quantitative real-time polymerase chain reaction. The role of DAB2IP in pancreatic cancer was further investigated in vitro and in vivo by upregulating DAB2IP in Bxpc-3 cells through transfection of DAB2IP into Bxpc-3 cells with recombinant lentivirus. The DAB2IP expression in pancreatic cancer cells and tissues with wild-type KRAS was significantly lower than that in cells and tissues with mutant KRAS (P < .05). In Bxpc-3 cells with wild-type KRAS, overexpression of DAB2IP decreased the expression of P-AKT and P-ERK and the Ras activity; increased the expression of P-JNK and caspase 3; inhibited cell proliferation, invasiveness, and migration; and increased the cell sensitivity to cetuximab. Overexpression of DAB2IP inhibited tumor progression in a mouse model. In conclusion, DAB2IP downregulates Ras activity in wild-type pancreatic cancer cells. Overexpression of DAB2IP decreases the Ras activity, inhibits cell proliferation, and increases sensitivity to cetuximab in wild-type pancreatic cancer cells. In conclusion, DAB2IP may serve as a potential molecular therapeutic target for the treatment of pancreatic cancer.Keywords
Funding Information
- Guangdong Natural Science Foundation (S2013020012746)
This publication has 31 references indexed in Scilit:
- Stat5 Regulates the Phosphatidylinositol 3-Kinase/Akt1 Pathway during Mammary Gland Development and TumorigenesisMolecular and Cellular Biology, 2014
- The Mechanism of DAB2IP in Chemoresistance of Prostate Cancer CellsClinical Cancer Research, 2013
- Both Internalization and AIP1 Association Are Required for Tumor Necrosis Factor Receptor 2-Mediated JNK SignalingArteriosclerosis, Thrombosis, and Vascular Biology, 2012
- Low expression of DAB2IP contributes to malignant development and poor prognosis in hepatocellular carcinomaJournal of Gastroenterology and Hepatology, 2011
- Differential Regulation of RasGAPs in CancerGenes & Cancer, 2011
- Epothilone B Confers Radiation Dose Enhancement in DAB2IP Gene Knock-Down Radioresistant Prostate Cancer CellsInternational Journal of Radiation Oncology*Biology*Physics, 2010
- Inactivation of Ras GTPase-activating proteins promotes unrestrained activity of wild-type Ras in human liver cancerJournal of Hepatology, 2010
- Pancreatic CancerNew England Journal of Medicine, 2010
- An oncogene–tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-κBNature Medicine, 2010
- AIP1 Recruits Phosphatase PP2A to ASK1 in Tumor Necrosis Factor–Induced ASK1-JNK ActivationCirculation Research, 2008